238 related articles for article (PubMed ID: 32182364)
1. Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum.
Ferreri AJM; Sassone M; Miserocchi E; Govi S; Cecchetti C; Corti ME; Mappa S; Arcaini L; Zaja F; Todeschini G; Mannina D; Calimeri T; Perrone S; Ponzoni M; Modorati G
Blood Adv; 2020 Mar; 4(6):1013-1019. PubMed ID: 32182364
[TBL] [Abstract][Full Text] [Related]
2. A case of conjunctival MALT lymphoma: successfully treated with solely extended rituximab therapy.
Celiker H; Toker E; Kaygusuz Atagunduz I
Int Ophthalmol; 2019 Mar; 39(3):687-691. PubMed ID: 29411260
[TBL] [Abstract][Full Text] [Related]
3. [The preliminary observation of intralesional rituximab administration in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma].
Yang JP; Pang X; Zhang K; Wang LL; Zhu Y
Zhonghua Yan Ke Za Zhi; 2020 Nov; 56(11):839-845. PubMed ID: 33152842
[No Abstract] [Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
5. A Case Report of Conjunctival Extranodal Marginal Zone Lymphoma Treated with Intralesional Rituximab Injection Therapy.
Yazicioglu T; Oklar M; Kocabas S; Karadag E; Elibol V; Tezcan ME
Ocul Immunol Inflamm; 2022 Aug; 30(6):1329-1333. PubMed ID: 36084297
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
[TBL] [Abstract][Full Text] [Related]
7. Intralesional rituximab in primary conjunctival follicular lymphoma relapsed.
Rodríguez Villa S; Ruiz Rodríguez MJ; Vargas Pabón M
Arch Soc Esp Oftalmol; 2017 Jul; 92(7):326-329. PubMed ID: 27986437
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva.
Nückel H; Meller D; Steuhl KP; Dührsen U
Eur J Haematol; 2004 Oct; 73(4):258-62. PubMed ID: 15347312
[TBL] [Abstract][Full Text] [Related]
9. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
10. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
Ferreri AJ; Govi S; Colucci A; Crocchiolo R; Modorati G
Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
[TBL] [Abstract][Full Text] [Related]
11. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M
Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930
[TBL] [Abstract][Full Text] [Related]
12. A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.
Kiesewetter B; Neuper O; Mayerhoefer ME; Dolak W; Lukas J; Simonitsch-Klupp I; Raderer M
Hematol Oncol; 2018 Feb; 36(1):49-55. PubMed ID: 28695630
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.
Pan D; Moskowitz CH; Zelenetz AD; Straus D; Kewalaramani T; Noy A; Qin J; Teruya-Feldstein J; Portlock CS
Cancer J; 2002; 8(5):371-6. PubMed ID: 12416894
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.
Leahy MF; Turner JH
Blood; 2011 Jan; 117(1):45-52. PubMed ID: 20864582
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
16. Results of Upfront Therapy for Marginal Zone Lymphoma.
Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
[TBL] [Abstract][Full Text] [Related]
17. Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna.
Kiesewetter B; Lamm W; Neuper O; Mayerhoefer ME; Simonitsch-Klupp I; Raderer M
Hematol Oncol; 2019 Oct; 37(4):345-351. PubMed ID: 31283840
[TBL] [Abstract][Full Text] [Related]
18. Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report.
Yang X; Min X; He W
Medicine (Baltimore); 2018 May; 97(21):e10845. PubMed ID: 29794780
[TBL] [Abstract][Full Text] [Related]
19. Intralesional interferon-α for conjunctival mucosa-associated lymphoid tissue lymphoma: long-term results.
Blasi MA; Tiberti AC; Valente P; Laguardia M; Sammarco MG; Balestrazzi A; Larocca LM; Balestrazzi E
Ophthalmology; 2012 Mar; 119(3):494-500. PubMed ID: 22226154
[TBL] [Abstract][Full Text] [Related]
20. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial.
Ferreri AJ; Sassone M; Kiesewetter B; Govi S; Scarfò L; Donadoni G; Raderer M
Ann Oncol; 2015 Aug; 26(8):1760-5. PubMed ID: 25935794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]